By: Norton Healthcare June 26, 2026
By: Norton Healthcare
June 26, 2026
ARST2034 – A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma